BARD1 germline pathogenic confers moderate breast-cancer risk (~2-3×). BARD1 forms hetero...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BARD1-GERMLINE-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BARD1 germline pathogenic |
| Disease | DIS-BREAST |
| ESCAT tier | IIA |
| Recommended combinations | standard breast therapy, olaparib off-label (HRR rationale) |
| Evidence summary | BARD1 germline pathogenic confers moderate breast-cancer risk (~2-3×). BARD1 forms heterodimer with BRCA1 → biological HR deficiency. Limited clinical PARPi data; off-label consideration. ESCAT IIA / OncoKB Level 3A. |
Notes
Cascade testing per NCCN. Enhanced screening recommended.
Used By
No reverse references found in the YAML corpus.